Symbols / COYA Stock $4.54 +5.83% Coya Therapeutics, Inc.
COYA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Ratings
Current target
$4.54
Low
$14.00
High
$18.00
Mean
$15.64
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-10 | main | D. Boral Capital | Buy → Buy | $15 |
| 2026-03-23 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2026-03-19 | main | D. Boral Capital | Buy → Buy | $15 |
| 2026-03-16 | main | Chardan Capital | Buy → Buy | $14 |
| 2026-03-16 | main | D. Boral Capital | Buy → Buy | $15 |
| 2026-02-18 | main | D. Boral Capital | Buy → Buy | $15 |
| 2026-02-02 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2026-01-21 | main | D. Boral Capital | Buy → Buy | $15 |
| 2026-01-08 | main | Chardan Capital | Buy → Buy | $14 |
| 2026-01-08 | main | D. Boral Capital | Buy → Buy | $15 |
| 2026-01-05 | main | D. Boral Capital | Buy → Buy | $15 |
| 2025-12-23 | main | D. Boral Capital | Buy → Buy | $15 |
| 2025-12-09 | main | D. Boral Capital | Buy → Buy | $15 |
| 2025-11-14 | main | Chardan Capital | Buy → Buy | $14 |
| 2025-11-13 | main | BTIG | Buy → Buy | $16 |
| 2025-11-12 | main | D. Boral Capital | Buy → Buy | $15 |
| 2025-09-30 | reit | BTIG | Buy → Buy | $15 |
| 2025-09-29 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-09-22 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-09-17 | main | D. Boral Capital | Buy → Buy | $18 |
- [ARS] Coya Therapeutics, Inc. SEC Filing - Stock Titan Wed, 13 May 2026 12
- Coya Therapeutics Establishes $30 Million ATM Equity Program - TipRanks ue, 12 May 2026 14
- Coya Therapeutics (COYA) 2026 proxy outlines director elections and auditor ratification - Stock Titan Wed, 13 May 2026 12
- Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million - TradingView ue, 12 May 2026 13
- Coya Therapeutics entered into sales agreement, may offer and sell from time to time shares of co's common stock for up to $30 million - marketscreener.com ue, 12 May 2026 14
- Coya Therapeutics to sell 2.522M shares at $4.40 in private placement - Yahoo Finance Sat, 31 Jan 2026 08
- Is Coya Therapeutics Stock Built to Withstand More Downside? - Trefis Wed, 24 Dec 2025 08
- Coya Therapeutics Updates Q1 Results, COYA 302 Progress - TipRanks ue, 12 May 2026 13
- H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock at $18 - Investing.com Mon, 05 Jan 2026 08
- Coya Therapeutics (COYA) Deepening Losses Challenge Bullish Growth Narrative After FY 2025 Results - simplywall.st Wed, 18 Mar 2026 07
- Experimental ALS therapy COYA 302 wins FDA Fast Track status - Stock Titan ue, 12 May 2026 11
- Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update - PR Newswire ue, 12 Aug 2025 07
- Coya Therapeutics Announces $11.1 Million Private Placement - Business Wire Fri, 30 Jan 2026 08
- Coya Therapeutics Announces Proposed Public Offering of Common Stock - October 23, 2025 - BioSpace hu, 23 Oct 2025 07
- Here’s Greenlight Capital’s Update on Coya Therapeutics (COYA) - Yahoo Finance ue, 28 Oct 2025 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
7.95
+123.57%
|
3.55
-40.79%
|
6.00
|
0.00
|
| Operating Revenue |
|
7.95
+123.57%
|
3.55
-40.79%
|
6.00
|
0.00
|
| Operating Expense |
|
30.50
+46.61%
|
20.80
+49.61%
|
13.91
+41.72%
|
9.81
|
| Research And Development |
|
19.02
+59.99%
|
11.89
+96.71%
|
6.04
+22.42%
|
4.94
|
| Selling General And Administration |
|
11.45
+28.85%
|
8.89
+13.43%
|
7.83
+61.61%
|
4.85
|
| General And Administrative Expense |
|
11.45
+28.85%
|
8.89
+13.43%
|
7.83
+61.61%
|
4.85
|
| Other Gand A |
|
11.45
+28.85%
|
8.89
+13.43%
|
7.83
+61.61%
|
4.85
|
| Total Expenses |
|
30.50
+46.61%
|
20.80
+49.61%
|
13.91
+41.72%
|
9.81
|
| Operating Income |
|
-22.56
-30.76%
|
-17.25
-118.26%
|
-7.90
+19.45%
|
-9.81
|
| Total Operating Income As Reported |
|
-22.56
-30.76%
|
-17.25
-118.26%
|
-7.90
+19.45%
|
-9.81
|
| EBITDA |
|
-22.53
-30.81%
|
-17.22
-118.67%
|
-7.88
+19.51%
|
-9.78
|
| Normalized EBITDA |
|
-22.53
-30.81%
|
-17.22
-118.67%
|
-7.88
-8.07%
|
-7.29
|
| Reconciled Depreciation |
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
|
| EBIT |
|
-22.56
-30.76%
|
-17.25
-118.26%
|
-7.90
+19.45%
|
-9.81
|
| Total Unusual Items |
|
—
|
—
|
-0.54
+78.24%
|
-2.50
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
-0.54
+78.24%
|
-2.50
|
| Special Income Charges |
|
—
|
—
|
-0.54
-3.46%
|
-0.53
|
| Other Special Charges |
|
—
|
—
|
0.54
+3.46%
|
0.53
|
| Net Income |
|
-21.23
-42.64%
|
-14.88
-86.29%
|
-7.99
+34.77%
|
-12.24
|
| Pretax Income |
|
-21.22
-36.04%
|
-15.60
-114.77%
|
-7.26
+40.68%
|
-12.24
|
| Net Non Operating Interest Income Expense |
|
—
|
—
|
—
|
—
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
—
|
| Net Interest Income |
|
—
|
—
|
—
|
—
|
| Interest Expense |
|
—
|
—
|
—
|
—
|
| Other Income Expense |
|
1.33
-19.19%
|
1.65
+157.86%
|
0.64
+126.28%
|
-2.43
|
| Other Non Operating Income Expenses |
|
1.33
-19.19%
|
1.65
+157.86%
|
0.64
+904.14%
|
0.06
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
-2.50
|
| Tax Provision |
|
0.00
+100.43%
|
-0.72
-199.51%
|
0.72
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+352.59%
|
0.00
-77.90%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-21.23
-42.64%
|
-14.88
-86.29%
|
-7.99
+34.77%
|
-12.24
|
| Net Income From Continuing Operation Net Minority Interest |
|
-21.23
-42.64%
|
-14.88
-86.29%
|
-7.99
+34.77%
|
-12.24
|
| Net Income From Continuing And Discontinued Operation |
|
-21.23
-42.64%
|
-14.88
-86.29%
|
-7.99
+34.77%
|
-12.24
|
| Net Income Continuous Operations |
|
-21.23
-42.64%
|
-14.88
-86.29%
|
-7.99
+34.77%
|
-12.24
|
| Normalized Income |
|
-21.23
-42.64%
|
-14.88
-86.29%
|
-7.99
+18.06%
|
-9.75
|
| Net Income Common Stockholders |
|
-21.23
-42.64%
|
-14.88
-86.29%
|
-7.99
+34.77%
|
-12.24
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
—
|
| Diluted EPS |
|
—
|
-0.98
-24.05%
|
-0.79
+83.30%
|
-4.73
|
| Basic EPS |
|
—
|
-0.98
-24.05%
|
-0.79
+83.30%
|
-4.73
|
| Basic Average Shares |
|
—
|
15.24
+49.93%
|
10.16
+292.40%
|
2.59
|
| Diluted Average Shares |
|
—
|
15.24
+49.93%
|
10.16
+292.40%
|
2.59
|
| Diluted NI Availto Com Stockholders |
|
-21.23
-42.64%
|
-14.88
-86.29%
|
-7.99
+34.77%
|
-12.24
|
| Depreciation Amortization Depletion Income Statement |
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
|
| Depreciation And Amortization In Income Statement |
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
|
| Depreciation Income Statement |
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
49.95
+12.63%
|
44.35
+7.48%
|
41.26
+391.48%
|
8.40
|
| Current Assets |
|
49.94
+12.71%
|
44.31
+7.55%
|
41.20
+473.37%
|
7.18
|
| Cash Cash Equivalents And Short Term Investments |
|
46.82
+22.13%
|
38.34
+17.51%
|
32.63
+449.86%
|
5.93
|
| Cash And Cash Equivalents |
|
46.82
+22.13%
|
38.34
+17.51%
|
32.63
+449.86%
|
5.93
|
| Receivables |
|
0.00
-100.00%
|
0.73
-90.26%
|
7.50
|
0.00
|
| Other Receivables |
|
—
|
—
|
7.50
|
—
|
| Taxes Receivable |
|
0.00
-100.00%
|
0.73
|
0.00
|
—
|
| Prepaid Assets |
|
3.12
-40.51%
|
5.24
+389.74%
|
1.07
-14.52%
|
1.25
|
| Total Non Current Assets |
|
0.01
-70.91%
|
0.04
-41.49%
|
0.07
-94.55%
|
1.21
|
| Net PPE |
|
0.01
-70.91%
|
0.04
-41.49%
|
0.07
-29.32%
|
0.09
|
| Gross PPE |
|
—
|
0.14
+0.00%
|
0.14
+0.00%
|
0.14
|
| Accumulated Depreciation |
|
—
|
-0.10
-38.62%
|
-0.07
-62.91%
|
-0.04
|
| Other Properties |
|
—
|
0.14
+0.00%
|
0.14
+0.00%
|
0.14
|
| Non Current Deferred Assets |
|
—
|
—
|
0.00
-100.00%
|
1.12
|
| Total Liabilities Net Minority Interest |
|
6.92
+45.12%
|
4.77
-15.23%
|
5.63
-66.49%
|
16.79
|
| Current Liabilities |
|
5.87
+53.53%
|
3.82
-24.30%
|
5.05
+32.13%
|
3.82
|
| Payables And Accrued Expenses |
|
4.67
+57.05%
|
2.98
-27.92%
|
4.13
+7.98%
|
3.82
|
| Payables |
|
1.06
-33.18%
|
1.59
-15.50%
|
1.88
+3.54%
|
1.82
|
| Accounts Payable |
|
1.06
-33.18%
|
1.59
+37.42%
|
1.16
-36.34%
|
1.82
|
| Current Accrued Expenses |
|
3.61
+160.29%
|
1.39
-38.29%
|
2.25
+12.00%
|
2.01
|
| Total Tax Payable |
|
—
|
0.00
-100.00%
|
0.72
|
0.00
|
| Income Tax Payable |
|
—
|
0.00
-100.00%
|
0.72
|
0.00
|
| Current Deferred Liabilities |
|
1.20
+41.21%
|
0.85
-8.11%
|
0.92
|
0.00
|
| Current Deferred Revenue |
|
1.20
+41.21%
|
0.85
-8.11%
|
0.92
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
1.05
+11.07%
|
0.95
+64.52%
|
0.57
-95.57%
|
12.97
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
12.97
|
| Long Term Debt |
|
—
|
—
|
—
|
12.97
|
| Non Current Deferred Liabilities |
|
1.05
+11.07%
|
0.95
+64.52%
|
0.57
|
0.00
|
| Non Current Deferred Revenue |
|
1.05
+11.07%
|
0.95
+64.52%
|
0.57
|
0.00
|
| Stockholders Equity |
|
43.03
+8.72%
|
39.58
+11.06%
|
35.64
+524.56%
|
-8.39
|
| Common Stock Equity |
|
43.03
+8.72%
|
39.58
+11.06%
|
35.64
+307.34%
|
-17.19
|
| Capital Stock |
|
0.00
+25.31%
|
0.00
+15.96%
|
0.00
-99.98%
|
8.79
|
| Common Stock |
|
0.00
+25.31%
|
0.00
+15.96%
|
0.00
+456.37%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
-100.00%
|
8.79
|
| Share Issued |
|
20.93
+25.30%
|
16.71
+15.98%
|
14.41
+48.82%
|
9.68
|
| Ordinary Shares Number |
|
20.93
+25.30%
|
16.71
+15.98%
|
14.41
+48.82%
|
9.68
|
| Additional Paid In Capital |
|
104.99
+30.73%
|
80.31
+30.59%
|
61.50
+8929.70%
|
0.68
|
| Retained Earnings |
|
-61.96
-52.11%
|
-40.74
-57.55%
|
-25.86
-44.70%
|
-17.87
|
| Total Equity Gross Minority Interest |
|
43.03
+8.72%
|
39.58
+11.06%
|
35.64
+524.56%
|
-8.39
|
| Total Capitalization |
|
43.03
+8.72%
|
39.58
+11.06%
|
35.64
+679.44%
|
4.57
|
| Working Capital |
|
44.07
+8.85%
|
40.48
+12.01%
|
36.14
+975.30%
|
3.36
|
| Invested Capital |
|
43.03
+8.72%
|
39.58
+11.06%
|
35.64
+944.11%
|
-4.22
|
| Total Debt |
|
—
|
—
|
—
|
12.97
|
| Net Debt |
|
—
|
—
|
—
|
7.03
|
| Net Tangible Assets |
|
43.03
+8.72%
|
39.58
+11.06%
|
35.64
+524.56%
|
-8.39
|
| Tangible Book Value |
|
43.03
+8.72%
|
39.58
+11.06%
|
35.64
+307.34%
|
-17.19
|
| Other Equity Interest |
|
—
|
—
|
-0.01
|
—
|
| Preferred Stock Equity |
|
—
|
—
|
—
|
8.79
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-10.74
-4.38%
|
-10.29
+8.04%
|
-11.19
-54.56%
|
-7.24
|
| Cash Flow From Continuing Operating Activities |
|
-10.74
-4.38%
|
-10.29
+8.04%
|
-11.19
-54.56%
|
-7.24
|
| Net Income From Continuing Operations |
|
-21.23
-42.64%
|
-14.88
-86.29%
|
-7.99
+34.77%
|
-12.24
|
| Depreciation Amortization Depletion |
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
|
| Depreciation |
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
|
| Depreciation And Amortization |
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
|
| Other Non Cash Items |
|
2.29
+9058.41%
|
0.03
-95.40%
|
0.54
-86.48%
|
4.02
|
| Stock Based Compensation |
|
4.29
+61.08%
|
2.66
+205.36%
|
0.87
+320.67%
|
0.21
|
| Change In Working Capital |
|
3.88
+106.79%
|
1.88
+140.40%
|
-4.64
-717.66%
|
0.75
|
| Change In Receivables |
|
0.00
-100.00%
|
7.50
+200.00%
|
-7.50
|
0.00
|
| Change In Prepaid Assets |
|
2.85
+158.22%
|
-4.90
-2796.16%
|
0.18
+119.75%
|
-0.92
|
| Change In Payables And Accrued Expense |
|
0.57
+156.12%
|
-1.02
-186.75%
|
1.18
-29.61%
|
1.67
|
| Change In Accrued Expense |
|
1.10
+173.41%
|
-1.50
-270.66%
|
0.88
+6.21%
|
0.83
|
| Change In Payable |
|
-0.53
-210.38%
|
0.48
+59.78%
|
0.30
-64.65%
|
0.85
|
| Change In Account Payable |
|
-0.53
-210.38%
|
0.48
+59.78%
|
0.30
-64.65%
|
0.85
|
| Change In Other Working Capital |
|
0.45
+53.49%
|
0.30
-80.24%
|
1.50
|
—
|
| Investing Cash Flow |
|
-1.16
-4558.41%
|
-0.03
+95.40%
|
-0.54
-3.46%
|
-0.53
|
| Cash Flow From Continuing Investing Activities |
|
-1.16
-4558.41%
|
-0.03
+95.40%
|
-0.54
-3.46%
|
-0.53
|
| Net PPE Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of PPE |
|
—
|
—
|
—
|
0.00
|
| Capital Expenditure |
|
—
|
—
|
—
|
—
|
| Net Other Investing Changes |
|
-1.16
-4558.41%
|
-0.03
+95.40%
|
-0.54
-3.46%
|
-0.53
|
| Financing Cash Flow |
|
20.39
+27.21%
|
16.03
-58.29%
|
38.43
+310.62%
|
9.36
|
| Cash Flow From Continuing Financing Activities |
|
20.39
+27.21%
|
16.03
-58.29%
|
38.43
+310.62%
|
9.36
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
0.00
-100.00%
|
10.47
|
| Issuance Of Debt |
|
—
|
—
|
0.00
-100.00%
|
10.47
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
10.47
|
| Net Long Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
10.47
|
| Net Common Stock Issuance |
|
20.35
+45.30%
|
14.00
-63.47%
|
38.34
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.04
-98.21%
|
2.14
+2282.63%
|
0.09
+56828.48%
|
0.00
|
| Net Other Financing Charges |
|
—
|
-0.12
|
—
|
-1.11
|
| Changes In Cash |
|
8.48
+48.49%
|
5.71
-78.60%
|
26.69
+1575.10%
|
1.59
|
| Beginning Cash Position |
|
38.34
+17.51%
|
32.63
+449.86%
|
5.93
+36.72%
|
4.34
|
| End Cash Position |
|
46.82
+22.13%
|
38.34
+17.51%
|
32.63
+449.86%
|
5.93
|
| Free Cash Flow |
|
-10.74
-4.38%
|
-10.29
+8.04%
|
-11.19
-54.56%
|
-7.24
|
| Common Stock Issuance |
|
20.35
+45.30%
|
14.00
-63.47%
|
38.34
|
0.00
|
| Issuance Of Capital Stock |
|
20.35
+45.30%
|
14.00
-63.47%
|
38.34
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-05-12 View
- 10-Q2026-05-12 View
- 8-K2026-05-12 View
- 42026-04-09 View
- 8-K2026-04-02 View
- 10-K2026-03-16 View
- 8-K2026-03-16 View
- 8-K2026-01-30 View
- 42026-01-26 View
- 42026-01-26 View
- 42026-01-26 View
- 42026-01-26 View
- 8-K2026-01-20 View
- 8-K2026-01-08 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 8-K2025-12-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|